Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours

  • Technology appraisal guidance
  • TA86
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The Assessment Report for this appraisal was prepared by the West Midlands Health Technology Collaboration.

Wilson J, Connock M, Song F, et al. Imatinib for gastro-intestinal tumours. October 2003.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to make submissions and comment on the draft scope, Assessment Report and the Appraisal Consultation Document (ACD). Consultee organisations are provided with the opportunity to appeal against the Final Appraisal Determination.

I) Manufacturer/sponsors:

  • Novartis

II) Professional/specialist and patient/carer groups:

  • Association of Upper GI Surgeons

  • Barking and Dagenham Primary Care Trust

  • British Association of Surgical Oncology

  • British Oncology Pharmacy Association

  • CancerBACUP

  • Department of Health

  • Long-Term Medical Conditions Alliance

  • National Council for Hospice and Specialist Palliative Care Services

  • Newark and Sherwood Primary Care Trust

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal Pharmaceutical Society

  • Sarcoma UK

  • Tenovus Cancer Information Centre

  • Welsh Assembly Government

III) Commentator organisations (without the right of appeal):

  • British National Formulary

  • Cancer Research UK

  • Institute of Cancer Research

  • National Cancer Research Institute

  • NHS Confederation

  • NHS Quality Improvement Scotland

C. The following individuals were selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on imatinib for the treatment of GIST by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr David B Cook, Patient Representative, Life Raft, nominated by CancerBACUP

  • Professor Ian Judson, Professor of Cancer Pharmacology, Institute of Cancer Research, nominated by The Institute of Cancer Research andThe Royal College of Physicians

  • Professor PJ O'Dwyer, Professor of Gastrointestinal Surgery, Western Infirmary, Glasgow, nominated by British Association of Surgical Oncology andThe Institute of Cancer Research

  • Ms Sue Green, Senior Cancer Information Nurse, CancerBACUP, nominated by CancerBACUP

  • Dr Jeremy Whelan, Consultant Medical Oncologist, Meyerstein Institute of Oncology, Middlesex Hospital, UCLH NHS Trust, London